SynCardia Selected as Finalist for 2011 World Technology Award
Award Recognizing Visionary Contribution to Science and Technology to be Presented Oct. 26 in Association with TIME, Fortune and CNN at United Nations
TUCSON, Ariz. – Sept. 14, 2011 – SynCardia Systems, Inc., manufacturer of the world's only FDA, Health Canada and CE approved Total Artificial Heart, announced today that it has been selected as a finalist for the 2011 World Technology Award for Health & Medicine. The award, which honors those doing "innovative work of the greatest likely long-term significance" in science, technology and related fields, is presented by the World Technology Network (WTN) in association with TIME, Fortune, CNN, Science/AAAS and Technology Review.
"Through the peer-nomination and peer-review process, we uncover the best of the best of the best in science and technology," says James P. Clark, Founder and Chairman of WTN. "We discover whose work is going to have the greatest likely impact over time. The World Technology Awards give a snapshot of the amazing science and technology revolutions in process."
SynCardia is currently conducting an FDA-approved Investigational Device Exemption (IDE) clinical study of its Freedom® portable driver, the first wearable power supply for the SynCardia temporary Total Artificial Heart. For the first time in U.S. history, stable patients who meet study criteria are leaving the hospital without human hearts to wait for a matching donor heart at home. Prior to the development of the Freedom driver, U.S. Total Artificial Heart patients were confined to the hospital for months, sometimes years while they waited for a transplant because the only FDA-approved driver, "Big Blue," is hospital-based and weighs 418 pounds.
The other 5 finalists in the Health & Medicine category include:
- Bio-Path Holdings – developed drug delivery technology that provides systemic distribution of nucleic acid drugs through simple intravenous transfusion
- Institute of Microelectronics, Singapore – developed a real-time multifunctional integrated electrocardiogram (ECG) signal processing scheme
- NeuroPace – developed technology designed to decrease or eliminate epilepsy episodes through an implant which monitors the patient's brain, and delivers electric signals to prevent seizures by disrupting any abnormal activity
- Second Sight Medical Products – created a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations
- SpectraScience – developed a technology platform to instantly determine if tissue is normal, pre-cancer or cancerous, without the need for exploratory biopsy.
The winners of the World Technology Awards will be announced during a ceremony at the United Nations on October 26, at the close of the two-day World Technology Summit.
CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, email@example.com, (520) 547-7463